Background: In large-caliber pial macrofistulae (pMF), the combination of high blood flow velocity and large efferent artery diameter makes control over the endovascular vessel occlusion difficult and may result in the inadvertent venous passage of occlusive devices or embolic agents. Case descriptions: Patient 1: A 27-year-old man presented with headache and ataxia. An infratentorial pMF supplied by both superior cerebellar arteries with venous ectasia was found. The first treatment attempt using balloons and coils failed since the position of either device could not be controlled because of a distal diameter of the feeding artery of 8 mm. In a second session a pCANvas1 (phenox) was deployed at the level of the arteriovenous connection and adenosine-induced asystole allowed the controlled injection of nBCA/Lipiodol with partial occlusion of the pMF. A remaining arteriovenous shunt was occluded under asystole in a third session. The procedures were well tolerated, the patient returned to normal and DSA confirmed the occlusion of the fistula. Patient 2: A 13-year-old boy with hereditary hemorrhagic teleangiectasia presented with an intracerebral hemorrhage from an aneurysm of the left MCA. Twelve weeks after the aneurysm treatment a feeding MCA branch (diameter 4.5 mm) of a right frontal pMF was catheterized. The macrofistula was occluded by deployment of a pCANvas1, followed by the injection of nBCAl/Lipiodol under adenosine-induced asystole. Conclusion: pCANvas1 and adenosine-induced asystole allow a controlled injection of nBCA/Lipiodol for the endovascular occlusion of high-flow pMF without venous passage of the embolic agent.
Introduction
Congenital pial arteriovenous macrofistulae are rare cerebrovascular malformations characterized by a direct large-caliber connection between a single or multiple pial arteries and draining veins. 1 Because of the large shunt volume they frequently become symptomatic early in life. High-output cardiac failure in the newborn, mass effect of the dilated draining veins and intracranial hemorrhage are the possible sequelae of these fistulas. 2 Conservative management is not a viable option for most patients. Successful surgical occlusion has been reported. 3 The endovascular occlusion is often straightforward. 4 The goal of the endovascular procedure is the vessel occlusion at the site of the arteriovenous connection. Some level of proximal artery occlusion is mostly unavoidable and acceptable. Occlusion of draining veins distal to the fistula may trigger massive hemorrhage and has to be avoided. Detachable balloons and coils alone or together with liquid embolic agents are most frequently used in this context. 5, 6 Technical challenges for endovascular treatment can be encountered in the case of large-diameter afferent arteries and a large-caliber arteriovenous connection together with a very high blood flow velocity. These features may prevent the accurate and controlled placement of any occlusive device or agent.
We describe a pial arteriovenous macrofistula in which the attempted occlusion with balloons and coils had failed. The patient was successfully treated using an unconventional combination of an intra-aneurysmal flow diverter and adenosine-induced asystole, which allowed the controlled injection of n-butyl 2-cyanoacrylate (nBCA)/Lipiodol. While the exact repetition of this treatment strategy will unlikely occur, we wanted to show how some creativity may help to overcome procedural challenges and allow for a safe and successful treatment.
Case descriptions Patient 1
This 27-year-old otherwise healthy man presented with unbearable headache for the last four weeks and progressive ataxia. Magnetic resonance imaging (MRI) showed a huge vascular malformation in the posterior fossa with dilated veins (Figure 1(a) ). The lateral ventricles and the third ventricle were dilated. Digital subtraction angiography (DSA) revealed an arteriovenous macrofistula with pial supply from both superior cerebellar arteries, most likely with separate fistulae in the wall of the draining vein (Figure 1(b) and (c)).
The patient was offered endovascular treatment. Since technical difficulty was anticipated, the informed consent conversation included a notion that increased risks and possibly the use of unapproved or uncertified implants or methods may be required. The patient confirmed his consent with this proposal in written form.
During a first treatment session under general anesthesia, the attempted occlusion of the left superior cerebellar artery (SCA) failed. Several balloons, both detachable and non-detachable, and coils were inserted (Balloons: Scepter C 4/10, Scepter XC 4/11, MicroVention; Goldvalve 9/16, Balt; Transform 7/7, Stryker; Coils: Target XL360 22/50, Target XL360 10/40, Stryker). They instantaneously migrated into the draining veins due to a distal vessel diameter of about 8 mm ( Figure 1(d) ). This happened during several deployments and the procedure was stopped.
The second procedure was scheduled six days later. Since induced asystole was contemplated, the patient underwent a cardiological examination, which did not reveal any abnormalities. For the second procedure (again under general anesthesia) a bilateral femoral 8F access was used. A 4F central venous access was established from the right femoral vein, with a 4F catheter (Tempo4 vertebral, Cordis) in front of the right atrium. The left SCA was catheterized with a microcatheter (Marathon/Mirage, Medtronic). The injection of this vessel confirmed that the use of a coil together with acrylic glue or Onyx would, despite the planned injection under asystole, most likely end in an uncontrolled venous passage. It was decided to use a detachable intrasaccular flow diverter (pCANvas1, phenox) together with the injection of polymer glue under induced asystole. The left SCA was catheterized with an Excelsior XT27 microcatheter (Stryker). A pCANvas1 (4 mm shaft diameter, 20 mm shaft length, 10 mm petal diameter; phenox) was deployed in a way that brought the distal end of the device with its membrane to the level of the arteriovenous transition (Figure 1(e) ). A Marathon catheter (Medtronic) was placed with the distal tip at the level of the pCANvas1 shaft (Figure 1(f) ). As a liquid embolic agent, 0.8 cc glubran2 (GEM) was mixed with 0.8 cc Lipiodol (Guerbet). The Marathon catheter was carefully flushed with a 40% glucose solution. With a syringe containing the prepared glue connected to the Marathon catheter, 5 seconds of asystole was induced by a bolus injection of 36 mg adenosine (Adrekar, Sanofi-Aventis) via the venous 4 F catheter. During this phase, the dead space of the Marathon catheter (0.23 cc) was filled with glue. Upon onset of asystole, the glubran2/lipiodol mixture was slowly injected. As expected, solidification of the polymer started at the membrane of the pCANvas1 and the polymerized agent filled the distal segment of the left SCA and the connection to the draining vein ( Figure 1(g) ).
The pCANvas1 was subsequently detached electrolytically. The final DSA run showed the partial occlusion of the left SCA with some remaining supply of the fistula via the right and left SCA (Figure 1(h) ). The patient was discharged two days later and was heparinized for the following four weeks. A third treatment session was carried out 11 days later. A 1:1 glubran2/ lipiodol mixture was injected via the left SCA under 5 seconds of asystole induced by 42 mg of intravenous adenosine. The fistula was subsequently occluded, with intended venous passage of a small amount of the glue into the draining vein (Figure 1 
Patient 2
This 13-year-old boy was suffering from various manifestations of hereditary hemorrhagic teleangiectasia, including pulmonary arteriovenous fistulae and recurrent epistaxis. On January 31, 2017, he presented with a sudden left hemiplegia and became comatose. The computed tomography (CT) examination of his head showed a right frontal subarachnoid hemorrhage with a large right frontal intracerebral hematoma, a large aneurysm of the right middle cerebral artery (MCA) and pial macrofistulae of the right cerebellum and the right frontal lobe (Figure 2 (a) and (b)). A decompressive right frontal craniectomy was performed. After the clinical condition had stabilized the boy was referred for endovascular treatment. On admission the patient was able to perform voluntary minor movements of his left arm, hand and leg but could not overcome gravity. He had an incomplete left central facial palsy, no sensory deficit and normal cognition. The situation was extensively discussed with the parents, offering all potential treatment options for the ruptured aneurysm with the notion that both established methods (e.g. microsurgical clipping or balloon-assisted coil occlusion) as well as novel treatment strategies will be associated with increased risks. The parents eventually agreed with the below described procedures knowing that they would involve devices without ConformiteÉ urope´ene (CE) mark and without extensive previous clinical evaluation. On February 24, 2017, the right MCA aneurysm was treated by stent-assisted coil occlusion. By May 2017 the motor function of the left upper extremity had partially returned and he was able to walk with assistance. The left frontal lobe was protruding through the craniectomy and prevented the reconstruction of the skull bone. A partial treatment of the right frontal pial macrofistulae was therefore contemplated. DSA on May 10, 2017, confirmed the persistent occlusion of the MCA aneurysm and two pial macrofistulae as well as microfistulae and plexiform arteriovenous shunts in the right frontal lobe (Figure 2(c) ). A staged occlusion of this malformation was planned and initiated on May 12, 2017. Under general anesthesia, two 6F sheaths were inserted in both femoral arteries and two 4F sheaths were inserted in both femoral veins. A 4F catheter (Tempo4 vertebral, Cordis) was brought in front of the right atrium from the right femoral vein. A temporary pacemaker was inserted from the left femoral vein. Two 6F guide catheters (Guider Softip, Boston Scientific) were inserted into the right internal carotid artery. A hypertrophic right frontal MCA branch with a distal diameter of 4.5 mm supplying one of the macrofistulae was catheterized with a Marathon catheter using a Mirage wire (Medtronic) and with an Excelsior XT27 catheter using a Synchro2 0.014-inch wire (Stryker) (Figure 2(d) , posteroanterior view). The temporary pacemaker was set on 400 beats per minute for 30 seconds. During three stimulation phases repeated DSA runs did not show a significant slowing of the cerebral blood circulation. A pCANvas1 was therefore deployed at the level of the macrofistula. The Marathon catheter (Medtronic) was placed with the distal tip in the shaft of the pCANvas1 (Figure 2(e) ). As a liquid embolic agent 1 cc of Histoacryl (B. Braun) was mixed with 1.5 cc Lipiodol (Guerbet). The Marathon catheter was purged with a 40% glucose solution. With a syringe filled with the Histoacryl/Lipiodol mixture connected to the Marathon catheter, 8 seconds of asystole was induced by a bolus injection of 36 mg adenosine (Adrekar, Sanofi-Aventis) via the venous 4 F catheter. During asystole, the Histoacryl/Lipiodol mixture was slowly injected and solidified in the shaft of the pCANvas1 (Figure 2(f) ). The pCANvas1 was detached thereafter. A final DSA run showed the occlusion of the concerning macrofistula (Figure 2(g) ). The patient was discharged three days later in an unchanged clinical condition, expecting further treatment sessions.
Discussion
The key aspect in the treatment of a pial arteriovenous macrofistula is the occlusion of the connection between afferent artery or arteries and draining vein(s). Any damage to the artery and occlusion of the venous drainage must be avoided. Compromise of the veins may result in massive hemorrhage immediately after the procedure or with a latency of several days. 2, 7 Largecaliber arteriovenous connection and high blood flow velocity may interfere with the process of controlled, accurate vessel occlusion.
Coils, balloons, nBCA and Onyx (Medtronic) have been successfully used for the treatment of pial arteriovenous fistulas. 8 In our patient 1 both balloon catheters and coils were migrating from the afferent SCA into the draining vein. This prompted us to search for alternatives.
From extensive experience in the treatment of intracranial aneurysms, we are familiar with the new devices, which have become available during the last few years. 9 In the treatment of brain arteriovenous malformations (AVMs) and other vascular lesions, we used adenosine-induced asystole in more than 100 patients since the publication of Hashimoto et al. in 2000. 10, 11 Adenosine is an endogenous nucleoside with effect on the electrical conduction of the atrioventricular and the sinoatrial nodes. Via cardiac A1 receptors bradycardia, atrioventricular nodal blockade and sinus pauses are induced. The half-life time is about 10 seconds. We usually inject a standard dosage of 36 mg through a 4 F catheter at the level of the right atrium. Within seconds after the bolus injection, the onset of asystole can be expected and will last for 15-20 seconds, followed by spontaneous re-onset of sinus rhythm. Following the asystole, arterial hypo-or hypertension may be encountered. If necessary induced asystole can be repeated several times during a single endovascular procedure. Five and eight seconds of asystole in the patients reported here are exceptionally short.
Rapid ventricular pacing is an alternative method to achieve temporary circulatory arrest. 12 It was attempted in patent 2 and failed. In general we prefer the adenosine injection for practical reasons.
It is presently unknown if a pCANvas alone is sufficient to prevent the venous passage of the liquid embolic agent and if therefore induced asystole can be avoided.
A UNO Micro Vascular Plug System (Medtronic) or a WEB (Microvention) might be usable for the same purpose via a 0.021-inch inner diameter (ID) microcatheter, especially if the target vessel has a smaller diameter and the insertion of a 0.027-inch ID microcatheter would be a concern. pCANvas1 (phenox) is an intrasaccular flow diverter that requires a 0.027-inch ID microcatheter (Figure 3 ). Four distal petals with a wingspan between 5 and 12 mm are covered by a membrane and are connected to a proximal porous stent shaft. The device is connected to an insertion wire and can be electrolytically detached. The distal crown with a diameter of 10 mm was expected to exert a significant hemodynamic effect. The shaft length of 20 mm provided enough distance of the polymer cast from the detachment zone to avoid a fixation of the insertion wire. Another concern was the potential dissection of the sometimes quite fragile feeding arteries of pial macrofistulae due to the diameter discrepancy between the two vessels (8 mm in patient 1, 4.5 mm in patient 2) and the 10 mm crown wingspan of the pCANvas1. The risk was considered limited since pCANvas1 has been used inside aneurysms, which are most likely even more delicate. The pCANvas1 worked adequately in both patients and prevented a venous passage of the polymerizing glue.
The incomplete occlusion of the fistula in patient 1 was accepted since gradual occlusion together with the heparinization may prevent an excessive abrupt thrombus formation in the draining veins. The short phases of induced asystole, encountered in both patients during three treatment sessions, is unusual and might be related to the large shunt volume during the first treatment session in patient 1 and in patient 2, but remains unexplained for the second session in patient 1, when the shunt volume was already reduced.
The intended position of pCANvas1 should be as close as possible to the site of the pathological arteriovenous connection, but not inside the draining veins in order to avoid proximal occlusion as well as venous passage of the glue. An undersized device may not have a sufficient hemodynamic effect, which can be avoided if the diameter of the crown of the pCANvas is larger than the vessel diameter. It should be mentioned that the use of pCANvas1 substantially increases the cost of this procedure by about E12,000.-.
Conclusion
A stent-derivative (pCANvas1) and adenosine-induced asystole allow a controlled injection of nBCA without venous passage for the endovascular occlusion of highflow pial macrofistulae. Figure 3 . pCANvas1 (phenox) is an intrasaccular flow diverter. Insertion requires a 0.027-inch inner diameter microcatheter. Four distal petals are covered by a membrane and are connected to a proximal porous stent shaft. The device is connected to an insertion wire and can be electrolytically detached.
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